eligibility_summary
Adults (≥18) with systemic lupus erythematosus, active despite glucocorticoids plus ≥2 other immunosuppressants tried ≥12 weeks within the past 24 months, and with anti-dsDNA, anti-histone, anti-chromatin, and/or anti-Sm antibodies at screening. Excludes severe active lupus nephritis or CNS lupus/SLE neurologic symptoms, poorly controlled major chronic illness, and pregnancy or lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06038474: Phase II, single-arm trial in adults with systemic lupus erythematosus testing Descartes-08, an autologous BCMA-directed CAR T-cell therapy (cell-based immunotherapy). Mechanism: patient T cells are engineered to express a chimeric antigen receptor against B‑cell maturation antigen (BCMA), enabling targeted killing of BCMA+ plasmablasts/plasma cells to deplete autoantibody-producing cells and recalibrate humoral autoimmunity. Targets: BCMA and the antibody-secreting cell compartment of the B‑cell lineage, impacts the BAFF/APRIL–BCMA survival pathway and autoantibody production (e.g., anti-dsDNA, anti-Sm).